Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.

@article{Meyer2014CapecitabineAS,
  title={Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.},
  author={Tim Meyer and Wendi Qian and Martyn Evan Caplin and Graham Armstrong and Si-houy Lao-Sirieix and Richard M Hardy and Juan W Valle and Denis Talbot and David C. Cunningham and Nick Simon Reed and Ashley S. Shaw and Shaunak Navalkissoor and T V Luong and Pippa G. Corrie},
  journal={European journal of cancer},
  year={2014},
  volume={50 5},
  pages={902-11}
}
BACKGROUND Cytotoxic chemotherapy is widely used for advanced, unresectable pancreatic and other gastrointestinal foregut neuroendocrine tumours (NETs) and the most commonly used regimen combines 5-fluorouracil with streptozocin. The NET01 trial was designed to investigate whether capecitabine combined with streptozocin was an acceptable regimen with or without adding cisplatin. METHODS Patients with advanced, unresectable NETs of pancreatic, gastrointestinal foregut or unknown primary site… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
15 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…